NETS | Jotup

RLS AND EVERGREEN THERAGNOSTICS LAUNCH PARTNERSHIP FOR SALE AND DISTRIBUTION OF NEUROENDOCRINE TUMOR DIAGNOSTIC OCTEVY™ (KIT FOR PREPARATION OF GA 68 DOTATOC INJECTION), PENDING FDA APPROVAL

Retrieved on:

목요일, 5월 18, 2023

NETS, Partnership, Evergreen, Cancer, PET, NET, Food and Drug Administration Amendments Act of 2007, Hospital, Patient, Physician, RLS, Growth, FDA, Food, Pharmaceutical industry, Medical imaging

LAKE ZURICH, Ill. and SPRINGFIELD, N.J., May 18, 2023 /PRNewswire/ -- Today, RLS (USA) Inc., the third-largest nuclear medicine pharmacy network in the US, and Evergreen Theragnostics, Inc., a radiopharmaceutical company focused on improving the available options for cancer patients, announced a new agreement for RLS to prepare, sell and distribute doses of the drug candidate OCTEVY™ to PET customers across the US, if the product is approved by the Food and Drug Administration (FDA).

Key Points:

"Finding good radiopharmacy partners is crucial as we prepare to bring our first product to market," said James Cook, CEO of Evergreen Theragnostics.
"This partnership is an important step forward for RLS as we add new products to our portfolio and expand our capabilities.
As RLS continues to scale for sustainable growth, partnering with innovative industry leaders like Evergreen will be key," said Stephen Belcher, CEO of RLS.
RLS COO Trey Bankson added, "Evergreen continues to demonstrate its commitment to being at the cutting-edge of theragnostics.

RLS AND EVERGREEN THERAGNOSTICS LAUNCH PARTNERSHIP FOR SALE AND DISTRIBUTION OF NEUROENDOCRINE TUMOR DIAGNOSTIC OCTEVY™ (KIT FOR PREPARATION OF GA 68 DOTATOC INJECTION), PENDING FDA APPROVAL

Retrieved on:

목요일, 5월 18, 2023

NETS, Partnership, Evergreen, Cancer, PET, NET, Food and Drug Administration Amendments Act of 2007, Hospital, Patient, Physician, RLS, Growth, FDA, Food, Pharmaceutical industry, Medical imaging

LAKE ZURICH, Ill. and SPRINGFIELD, N.J., May 18, 2023 /PRNewswire/ -- Today, RLS (USA) Inc., the third-largest nuclear medicine pharmacy network in the US, and Evergreen Theragnostics, Inc., a radiopharmaceutical company focused on improving the available options for cancer patients, announced a new agreement for RLS to prepare, sell and distribute doses of the drug candidate OCTEVY™ to PET customers across the US, if the product is approved by the Food and Drug Administration (FDA).

Key Points:

"Finding good radiopharmacy partners is crucial as we prepare to bring our first product to market," said James Cook, CEO of Evergreen Theragnostics.
Evergreen is proud to partner with RLS as we prepare to bring OCTEVY™ to PET centers and NET patients across the country."
"This partnership is an important step forward for RLS as we add new products to our portfolio and expand our capabilities.
RLS COO Trey Bankson added, "Evergreen continues to demonstrate its commitment to being at the cutting-edge of theragnostics.

Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on:

화요일, 5월 16, 2023

REHOVOT, Israel, May 16, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the three months ended March 31, 2023.

Key Points:

The acquisition provides Purple Biotech with a technology platform for tri-specific antibody compounds and offers the potential to further expand to additional targets.
On March 16, 2023, Purple Biotech shared new results from exploratory analyses from a Phase 1 dose escalation study that assessed the safety and tolerability of CM24 plus nivolumab ( NCT04731467 ).
On April 19, 2023, Purple Biotech announced research findings at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando.
Purple Biotech announced on April 25, 2023, the inauguration of its Scientific Advisory Board (SAB).

Global Payment Security Software Market to Register Phenomenal Gains says BrandEssence Market Research

Retrieved on:

화요일, 5월 16, 2023

With this research report, businesses can gain a better understanding of the payment security software market and make informed decisions about their strategies and investments.

Key Points:

With this research report, businesses can gain a better understanding of the payment security software market and make informed decisions about their strategies and investments.
The Global Payment Security Software Market is anticipated to amass notable gains over assessment timeline of 2022-2029.
Payment security software is referred to as a type of software which safeguard's a user's data, privacy, and money during digital transactions.
Bargaining power of buyers: The bargaining power of buyers in the payment security software market is moderate to high.

Global Payment Security Software Market to Register Phenomenal Gains says BrandEssence Market Research

Retrieved on:

화요일, 5월 16, 2023

With this research report, businesses can gain a better understanding of the payment security software market and make informed decisions about their strategies and investments.

Key Points:

With this research report, businesses can gain a better understanding of the payment security software market and make informed decisions about their strategies and investments.
The Global Payment Security Software Market is anticipated to amass notable gains over assessment timeline of 2022-2029.
Payment security software is referred to as a type of software which safeguard's a user's data, privacy, and money during digital transactions.
Bargaining power of buyers: The bargaining power of buyers in the payment security software market is moderate to high.

RadioMedix and Orano Med Complete Patient Enrolment in Phase II Trial of Targeted Alpha-Emitter AlphaMedix in Neuroendocrine Cancers

Retrieved on:

화요일, 5월 16, 2023

RadioMedix and Orano Med, two clinical stage radiopharmaceutical companies, today announced that the last patient has been dosed in the Phase II trial of the targeted alpha emitter therapy, 212Pb-DOTAMTATE (AlphaMedix™).

Key Points:

RadioMedix and Orano Med, two clinical stage radiopharmaceutical companies, today announced that the last patient has been dosed in the Phase II trial of the targeted alpha emitter therapy, 212Pb-DOTAMTATE (AlphaMedix™).
“Previous studies have shown targeted alpha therapy (TAT) with AlphaMedix™ is well-tolerated.
Julien Dodet, President, and Chief Executive Officer of Orano Med, noted: “Completing this Phase II trial enrolment on schedule is a great achievement everyone involved and confirms the strong interest of the medical community for targeted alphatherapies with lead-212.
This reinforces Orano Med’s commitment to make innovative lead-212-based therapies available to the medical community and patients worldwide.”

Global Arena Holding Updates Shareholders on Expanding Business Opportunities

Retrieved on:

목요일, 5월 11, 2023

Reporting companies and funds must comply with the SEC’s proxy rules whenever its management submits proposals to shareholders that will be subject to a shareholder vote.

Key Points:

Reporting companies and funds must comply with the SEC’s proxy rules whenever its management submits proposals to shareholders that will be subject to a shareholder vote.
Distribution of a daily vote report to authorized recipients starting 15 days prior to the annual meeting.
Monitor the vote count and determine if enough shares have been voted to reach the required quorum of shares outstanding.
He also participated in the development of databases from which financial and regulatory reporting was derived for local and global stakeholders.

VolitionRx Limited Announces First Quarter 2023 Financial Results and Business Update

Retrieved on:

수요일, 5월 10, 2023

NETS, Capital market, Conference call, Eastern Time Zone, Sepsis, David Heska Wanbli Weiden, Neutrophil extracellular traps, FDA, NYSE, Cryptocurrency, Management, Pharmaceutical industry, Security (finance), Volition, Conference

HENDERSON, Nev., May 10, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the first quarter ended March 31, 2023. Volition management will host a conference call tomorrow, May 11 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below.

Key Points:

Conference call to discuss financial and operational results scheduled for Thursday, May 11, at 8:30 a.m. U.S. Eastern Time
HENDERSON, Nev., May 10, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the first quarter ended March 31, 2023.
Volition management will host a conference call tomorrow, May 11 at 8:30 a.m. U.S. Eastern Time to discuss these results.
"It has been a phenomenal start to the year, with the launch of our Nu.Q® Vet Cancer Test through IDEXX's reference laboratory network.
The call will provide an update on important events which have taken place in the first quarter of 2023 and upcoming milestones.

Peel Therapeutics Describes Excessive NETosis Induction in Long COVID

Retrieved on:

목요일, 4월 13, 2023

SALT LAKE CITY, April 13, 2023 /PRNewswire/ -- Peel Therapeutics, an evolutionary-inspired, clinical-stage biotech company, announced research conducted by the company has been published in The Journal of Thrombosis and Haemostasis. The study, NETosis Induction Reflects COVID-19 Severity and Long COVID: Insights from a Two-Center Patient Cohort Study in Israel, evaluated the ability of blood from Israeli patients with Long COVID to induce neutrophil extracellular traps (NETs) as a marker of ongoing inflammation. NETs are sticky webs of DNA released by activated immunes cells that contribute to immunothrombosis (mini-clots) and fibrosis. Peel scientists also correlated NETosis potential with acute disease severity in COVID-19. The study concluded that NET inhibitors may be a possible treatment approach for COVID-19 and recommended additional research to confirm findings. Peel Therapeutics is developing first-in-class Neutrophil Targeting Peptides (NTPs) – originating from natural NET inhibitors in newborns – to block inflammation leading to immunothrombosis and fibrosis.

Key Points:

The study, NETosis Induction Reflects COVID-19 Severity and Long COVID: Insights from a Two-Center Patient Cohort Study in Israel , evaluated the ability of blood from Israeli patients with Long COVID to induce neutrophil extracellular traps (NETs) as a marker of ongoing inflammation.
In this study, Peel researchers examined NETs among people with and without COVID-19 and measured NET induction during and after infection.
The study concluded that increased NETosis induction can be detected in people with Long COVID, offering insight into the potential uses of NTPs and other NET inhibitors for the treatment of Long COVID.
People who experienced symptoms of Long COVID maintained higher NETosis induction compared to recovered convalescent patients.

Reltime appoints Chief Commercial Officer

Retrieved on:

월요일, 4월 3, 2023

OSLO, Norway, April 3, 2023 /PRNewswire/ -- Reltime is pleased to confirm that Bishwajit Choudhary has accepted the position of Chief Commercial Officer, starting today.

Key Points:

OSLO, Norway, April 3, 2023 /PRNewswire/ -- Reltime is pleased to confirm that Bishwajit Choudhary has accepted the position of Chief Commercial Officer, starting today.
Mr. Choudhary brings over two decades of experience from financial services industry where he held many leadership positions, Group SVP- Strategy at NETS, Chief Commercial Officer at UserTribe and Chief Revenue Officer at Zwipe.
We are now strengthening our commercial organization to speed up the onboarding of customers and alliance partners.
With deep insights and a trusted position in the banking industry, Bishwajit will bring immense value to Reltime as we scale our operations globally," said Marlene Julo, Co-Founder and Chairman of Reltime.